NextCure (NXTC) Competitors

NextCure logo
$6.45 -0.33 (-4.87%)
Closing price 04:00 PM Eastern
Extended Trading
$6.46 +0.00 (+0.08%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NXTC vs. NKTX, AVXL, NGEN, CLLS, and OTLK

Should you buy NextCure stock or one of its competitors? NextCure's main competitors and comparable companies include Nkarta (NKTX), Anavex Life Sciences (AVXL), NervGen Pharma (NGEN), Cellectis (CLLS), and Oncobiologics (OTLK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NextCure compare to Nkarta?

Nkarta (NASDAQ:NKTX) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Nkarta has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, NextCure has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Nkarta's return on equity of -48.58% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NkartaN/A -48.58% -36.26%
NextCure N/A -191.33%-125.95%

Nkarta presently has a consensus price target of $11.20, suggesting a potential upside of 886.78%. NextCure has a consensus price target of $20.00, suggesting a potential upside of 210.08%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nkarta
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Nkarta had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for NextCure. Nkarta's average media sentiment score of 0.67 beat NextCure's score of -0.35 indicating that Nkarta is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nkarta
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

NextCure is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/A-$104.08M-$1.73N/A
NextCureN/AN/A-$55.84M-$6.77N/A

80.5% of Nkarta shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nkarta beats NextCure on 12 of the 14 factors compared between the two stocks.

How does NextCure compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Anavex Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, NextCure has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

31.5% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anavex Life Sciences' return on equity of -11.43% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -11.43% -10.72%
NextCure N/A -191.33%-125.95%

In the previous week, Anavex Life Sciences had 13 more articles in the media than NextCure. MarketBeat recorded 14 mentions for Anavex Life Sciences and 1 mentions for NextCure. Anavex Life Sciences' average media sentiment score of 0.07 beat NextCure's score of -0.35 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 3,485.43%. NextCure has a consensus price target of $20.00, indicating a potential upside of 210.08%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Anavex Life Sciences is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A
NextCureN/AN/A-$55.84M-$6.77N/A

Summary

Anavex Life Sciences beats NextCure on 10 of the 13 factors compared between the two stocks.

How does NextCure compare to NervGen Pharma?

NextCure (NASDAQ:NXTC) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

NextCure currently has a consensus target price of $20.00, suggesting a potential upside of 210.08%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 658.81%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
NervGen Pharma
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.83

NextCure's return on equity of -191.33% beat NervGen Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -191.33% -125.95%
NervGen Pharma N/A -298.52%-138.90%

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, NervGen Pharma had 6 more articles in the media than NextCure. MarketBeat recorded 7 mentions for NervGen Pharma and 1 mentions for NextCure. NervGen Pharma's average media sentiment score of -0.28 beat NextCure's score of -0.35 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
NervGen Pharma
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NervGen Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$6.77N/A
NervGen PharmaN/AN/A-$31.64M-$0.46N/A

Summary

NervGen Pharma beats NextCure on 8 of the 13 factors compared between the two stocks.

How does NextCure compare to Cellectis?

Cellectis (NASDAQ:CLLS) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Cellectis has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market. Comparatively, NextCure has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

NextCure has lower revenue, but higher earnings than Cellectis. NextCure is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$25.17M3.66-$67.59M-$1.27N/A
NextCureN/AN/A-$55.84M-$6.77N/A

Cellectis currently has a consensus target price of $5.46, suggesting a potential upside of 495.42%. NextCure has a consensus target price of $20.00, suggesting a potential upside of 210.08%. Given Cellectis' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectis is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NextCure has a net margin of 0.00% compared to Cellectis' net margin of -396.85%. NextCure's return on equity of -191.33% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-396.85% -319.93% -46.54%
NextCure N/A -191.33%-125.95%

In the previous week, NextCure had 1 more articles in the media than Cellectis. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Cellectis. Cellectis' average media sentiment score of 1.08 beat NextCure's score of -0.35 indicating that Cellectis is being referred to more favorably in the media.

Company Overall Sentiment
Cellectis Positive
NextCure Neutral

Summary

Cellectis beats NextCure on 12 of the 16 factors compared between the two stocks.

How does NextCure compare to Oncobiologics?

NextCure (NASDAQ:NXTC) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

42.7% of NextCure shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NextCure has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

NextCure currently has a consensus price target of $20.00, indicating a potential upside of 210.08%. Oncobiologics has a consensus price target of $5.20, indicating a potential upside of 1,233.33%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Oncobiologics' return on equity of 0.00% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -191.33% -125.95%
Oncobiologics N/A N/A -254.82%

In the previous week, Oncobiologics had 2 more articles in the media than NextCure. MarketBeat recorded 3 mentions for Oncobiologics and 1 mentions for NextCure. Oncobiologics' average media sentiment score of 0.67 beat NextCure's score of -0.35 indicating that Oncobiologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oncobiologics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NextCure has higher earnings, but lower revenue than Oncobiologics. NextCure is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$6.77N/A
Oncobiologics$1.35M70.33-$62.42M-$0.77N/A

Summary

Oncobiologics beats NextCure on 9 of the 14 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXTC vs. The Competition

MetricNextCureBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$29.54M$3.92B$7.42B$10.86B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-0.9523.5332.4528.84
Price / SalesN/A15.598.085.38
Price / CashN/A22.6520.7221.66
Price / Book5.384.124.313.50
Net Income-$55.84M-$24.03M$3.51B$394.12M
7 Day Performance0.78%-9.57%-7.89%-8.87%
1 Month Performance18.57%-13.67%-10.43%-11.97%
1 Year Performance-29.97%-6.29%-2.77%-9.56%

NextCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXTC
NextCure
2.7747 of 5 stars
$6.45
-4.9%
$20.00
+210.1%
-27.6%$29.54MN/AN/A40
NKTX
Nkarta
3.2172 of 5 stars
$1.35
-15.1%
$11.20
+729.6%
-37.4%$114.01MN/AN/A106
AVXL
Anavex Life Sciences
1.6226 of 5 stars
$1.13
-7.4%
$21.33
+1,787.9%
-81.5%$113.09MN/AN/A34
NGEN
NervGen Pharma
1.6815 of 5 stars
$1.33
-4.7%
$14.00
+952.6%
N/A$112.48MN/AN/A8
CLLS
Cellectis
3.0473 of 5 stars
$1.11
-0.9%
$5.46
+391.9%
-77.6%$112.38M$79.59MN/A229

Related Companies and Tools


This page (NASDAQ:NXTC) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners